Brief: Olema Oncology Announces New Clinical Data For Palazestrant In Combination With Ribociclib To Be Presented At The 2024 Esmo Breast Cancer Annual Congress
08/05/2024 12:19
May 8 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL DATA FOR
PALAZESTRANT IN
COMBINATION WITH RIBOCICLIB TO BE PRESENTED AT THE 2024 ESMO
BREAST CANCER ANNUAL CONGRESS
Source text for Eikon: ID:nGNX9TxyYF
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs